Stocktoria

Zentalis Pharmaceuticals, Inc. ZNTL

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-04-03

Zentalis Pharmaceuticals, Inc. statistics & valuation

Market cap$250.6M
P / B1.2×
Return on equity-63.4%
Return on capital-60.5%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2019202020212022202320242025
Operating margin (%)
-283.60% 2019202020212022202320242025
Return on equity (%)
-35.30% -43.50% -54.60% -66.80% -49.20% -63.40% 2019202020212022202320242025
Shares outstanding
5.6M 41.0M 45.5M 59.3M 70.8M 71.3M 71.9M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-52.20% -32.20% -34.90% -43.90% -53.00% -38.50% -47.40% 2019202020212022202320242025
Free cash flow margin (%)
-253.70% 2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$8.16 -$4.19 -$3.72 -$4.48 -$4.47 -$2.33 -$1.91 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin—-283.6%—————
Net margin—-246.0%—————
FCF margin—-253.7%—————
Return on assets-47.4%-38.5%-53.0%-43.9%-34.9%-32.2%-52.2%
Return on equity-63.4%-49.2%-66.8%-54.6%-43.5%-35.3%62.3%
Current ratio6.937.327.167.987.9812.074.62

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.